{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:27:57Z","timestamp":1790659677521,"version":"4.1.0"},"reference-count":59,"publisher":"Informa UK Limited","issue":"1-2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1080\/17512433.2024.2447776","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T10:47:17Z","timestamp":1735123637000},"page":"29-39","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Updates in innovation of the treatment of pyoderma gangrenosum"],"prefix":"10.1080","volume":"18","author":[{"given":"Heejo","family":"Keum","sequence":"first","affiliation":[{"name":"University of Texas Southwestern Medical Center","place":["Dallas, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina V.","family":"Zhivov","sequence":"additional","affiliation":[{"name":"University of Miami","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex G.","family":"Ortega-Loayza","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University","place":["Portland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01931-3"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042440"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01980"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15105"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.01.021"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31914-z"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.12463"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.130"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20474"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.5437"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-13"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.5980"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad420"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-023-02729-9"},{"key":"e_1_3_5_17_1","unstructured":"Oxford centre for evidence-based medicine: levels of evidence. 2009 Mar [cited 2024 Dec 10]. Produced by Phillips B Ball C Sackett D Badenoch D Straus S Haynes B Dawes M since November 1998. Updated by Howick J in March 2009. Available from: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2020.1709825"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-02829-0"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14397"},{"key":"e_1_3_5_21_1","unstructured":"10\u20132021-InflaRx announces positive data from third cohort of phase IIa open-label study with Vilobelimab in Pyoderma Gangraenosum. [cited 2024 Aug 10]. Available from: https:\/\/www.inflarx.de\/Home\/Investors\/Press-Releases\/10-2021-InflaRx-Announces-Positive-Data-from-Third-Cohort-of-Phase-IIa-Open-Label-Study-with-Vilobelimab-in-Pyoderma-Gangraenosum-0.html"},{"key":"e_1_3_5_22_1","unstructured":"Phase III trial to investigate efficacy and safety of Vilobelimab in ulcerative pyoderma gangrenosum. [cited 2024 Dec 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05964413"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01378-8"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.01.022"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad317"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03522.x"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.12.005"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.11.030"},{"key":"e_1_3_5_29_1","unstructured":"Guselkumab in the treatment of adults with pyoderma gangrenosum (PG) (GEORGE). [cited 2024 Sep 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06563323?cond=pyoderma%20gangrenosum&page=3&rank=26"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S374534"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/ASW.0000000000000129"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05560-1"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164080"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05418-y"},{"key":"e_1_3_5_35_1","unstructured":"Baricitinib in the treatment of adults with pyoderma gangrenosum (PG). [cited 2024 Aug 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04901325"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1067-1927.2005.1304S1.x"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13412"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.09.053"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.13303"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASW.0000725172.24316.fd"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2020.1160"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17048"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11236924"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.12910"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.12968\/jowc.2022.31.10.808"},{"issue":"9","key":"e_1_3_5_46_1","first-page":"40","article-title":"Dehydrated human Amnion\/Chorion membrane as adjunctive therapy in the multidisciplinary treatment of Pyoderma Gangrenosum: a case report","volume":"61","author":"Snyder RJ","year":"2015","unstructured":"Snyder RJ, Ead J, Glick B, et al. Dehydrated human Amnion\/Chorion membrane as adjunctive therapy in the multidisciplinary treatment of Pyoderma Gangrenosum: a case report. Ostomy Wound Manage. 2015;61(9):40\u201349.","journal-title":"Ostomy Wound Manage"},{"key":"e_1_3_5_47_1","unstructured":"A Novel Therapeutic Treatment of Pyoderma Gangrenosum. [cited 2024 Dec 30]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05120726"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11247532"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.152539"},{"key":"e_1_3_5_50_1","unstructured":"Autologous platelet-rich plasma therapy in the treatment of Pyoderma Gangrenosum. [cited 2024 Aug 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05984654"},{"issue":"3","key":"e_1_3_5_51_1","first-page":"247","article-title":"Mechanisms of action of hyperbaric oxygen therapy","volume":"41","author":"Camporesi EM","year":"2014","unstructured":"Camporesi EM, Bosco G. Mechanisms of action of hyperbaric oxygen therapy. Undersea Hyperb Med. 2014;41(3):247\u2013252.","journal-title":"Undersea Hyperb Med"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16228"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12189"},{"issue":"5","key":"e_1_3_5_54_1","first-page":"32","article-title":"Hyperbaric oxygen therapy for the adjunctive treatment of Pyoderma Gangrenosum: a case report","volume":"62","author":"Chiang IH","year":"2016","unstructured":"Chiang IH, Liao YS, Dai NT, et al. Hyperbaric oxygen therapy for the adjunctive treatment of Pyoderma Gangrenosum: a case report. Ostomy Wound Manage. 2016;62(5):32\u201336.","journal-title":"Ostomy Wound Manage"},{"key":"e_1_3_5_55_1","unstructured":"EU Clinical Trials Register. [cited 2024 Dec 10]. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-006013-11\/NL"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12822"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.3115"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/08941939.2020.1821134"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2017.06.005"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2008.02912.x"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00699-8"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2024.2447776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T08:47:22Z","timestamp":1739782042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2024.2447776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":59,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1080\/17512433.2024.2447776"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2024.2447776","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}